Bimeda® continually monitors the industry for new products and new product ideas. The companys development program is based on analyzing the market and providing those products that meet the needs of end-users.
The Bimeda® product line has evolved from four main sources: Company research and development; reformulating and repackaging established products to add value; reintroducing popular, but often hard-to-find existing products; and registering American versions of proven international products.
As part of Cross Vetpharm, Bimeda® shares in the company-wide commitment to research and development. Cross Vetpharm Group is an industry leader in its commitment to research. Annually, the company reinvests 7% of revenue back into research and development.
Every year perfectly safe and effective pharmaceuticals lose market share as new products appear. Bimeda® has been able to reinvigorate many of these therapeutic performers by reformulating and reintroducing them with additional features and benefits.
Other therapeutics remain popular, but have become difficult to find, as large companies turn their sales and marketing attention to higher margin, more expensive products.
With its lean marketing staff and efficient distribution network, Bimeda® has been able to keep these products alive and profitable.
In addition to its extensive new product development program, Cross Vetpharm Group markets in 70 countries worldwide. This global operation exposes the company to numerous animal health products suitable to the American market.
Bimeda® works with the parent company and regulatory agencies to attain approval and registration for the finest and most innovative of these products.
